📄 AIM ImmunoTech Inc. ($AIM)

📄 AIM ImmunoTech Inc. ($AIM) AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders. Its flagship product is Ampligen, a double-stranded RNA molecule being developed for globally important cancers, viral diseases, and disorders of the immune system, including myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Offering: $100,000,000 at $100,000,000 valuation Key risk: We have a history of operating losses and may never achieve or maintain profitability. Proceeds: general corporate purposes, working capital, capital expenditures, research and development, clinical trials, potential acquisitions

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders. Its flagship product is Ampligen, a double-stranded RNA molecule being developed for globally important cancers, viral diseases, and disorders of the immune system, including myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).